pivotal, we are unaware whether the assays used for lupus anticoagulant detection have been validated for postmortem blood collection and analysis.
Since APS is an acquired condition, testing for APLAs at autopsy for presumed implications for family members seems futile. The condition has scarcely been reported to run in families; however, it does not have a clear pattern of inheritance. Multiple factors (environmental and perhaps genetic) are likely to play a part in the risk of developing APS [5, 11] .
There are some reports implicating APLAs in the formation and progression of atherosclerotic lesions [5] . Notwithstanding, as more is learned about the natural history of the development of atherosclerosis, it is clear that the process that results in morbidity and mortality in adults has its origins in childhood and adolescence [12] . So the presence of atherosclerosis in young adults should not be considered as a manifestation of APS, since it is one of the least specific APS clinical pictures. Rather, it would appear that the increasing prevalence of traditional risk factors, such as hypertension, dyslipidemia, smoking, and diabetes mellitus are important in the early stages of the process.
Finally, thrombophilia screening is expensive and timeconsuming in clinical practice. It is natural for clinicians to want to look for the cause of thrombosis. However, it is only generally recommended that thrombophilia testing is performed where the management of the patient will be altered by the results, thereby calling into question the ancillary benefits of APS testing at autopsy [2, 13] .
